Trials / Recruiting
RecruitingNCT04684602
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 5,000 (estimated)
- Sponsor
- Thomas Advanced Medical LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.
Detailed description
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions. This study investigates clinical outcomes of treatments for numerous indications including: Autoimmune, Cardiovascular, Diabetes, Integumentary, Neurologic / Neurodegenerative, Pulmonary, Orthopedic Diseases, Sexual Dysfunction, Urologic Disorders and Viral Illnesses. Our hypotheses posit that regenerative treatments are both safe and statistically beneficial for a range of conditions. Outcomes will be determined by multiple valid outcome instruments that measure general quality of life information along with condition-specific information.
Conditions
- Autoimmune Diseases
- Cardiovascular Disorders
- Diabetes Complications
- Integumentary Disease
- Musculoskeletal Disorders
- Neurodegenerative Disorders
- Neurologic Disorders
- Pulmonary Disorders
- Sexual Dysfunction
- Urologic Disorders
- Viral Illness
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PrimePro™/ PrimeMSK™ | Injection via condition specific route of administration. |
Timeline
- Start date
- 2020-07-09
- Primary completion
- 2030-07-09
- Completion
- 2030-12-09
- First posted
- 2020-12-24
- Last updated
- 2022-04-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04684602. Inclusion in this directory is not an endorsement.